Table 1 Inclusion/Exclusion criteria

▪ Women aged ≥ 18 and < 40 years

▪ Frozen embryo transfer with artificial preparation

▪ Normal uterine cavity

▪ IVF/ICSI

▪ IVF cycle with GnRH agonist or antagonist

▪ Single day 5 blastocyst transfer

▪ Top quality embryo (at least Bl 3BA) at the moment of ET

▪ Participants can be included only once in the trial

▪ Body mass index of ≤ 18 and ≥ 29

▪ Previous diagnosis of PCOS/POI

▪ Endometriosis stage 3 and 4

▪ Previous diagnosis of hydrosalpinx

▪ Systemic diseases such as thyroid dysfunction, unless corrected

▪ History of recurrent implantation failure or recurrent miscarriage

▪ PGT-A and PGT-M cycles

▪ Oocytes donation cycles

▪ Known abnormal karyotype of the subject or of her partner/sperm donor, as applicable, depending on the source of sperm used for insemination in this trial. In case partner sperm will be used and the sperm production is severely impaired (concentration < 1 million/mL) normal karyotype, including no Y-chromosome microdeletion, must be documented

▪ Any known clinically significant systemic disease (e.g. insulin-dependent diabetes)

▪ Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events

▪ Current or past (within 90 days prior to screening) smoking habit of more than 10 cigarettes per day